In Vitro Antifungal Activity of Selected Essential Oils Against Drug-Resistant Clinical Spp. Strains
Authors
Affiliations
Background: Treatment options for aspergillosis include amphotericin B (AMB) and azole compounds, such as itraconazole (ITZ). However, serious side effects related to these antifungal agents are increasingly evident, and resistance continues to increase. Currently, a new trend in drug discovery to overcome this problem is represented by natural products from plants, or their extracts. Particularly, there is a great interest in essential oils (EOs) recognized for their antimicrobial role towards bacteria, fungi and viruses.
Methods: In this study, we evaluated the antifungal activity of eleven commercial EOs-clove, eucalyptus, geranium, hybrid lavender, lavender, lemon, lemongrass, neroli, oregano, tea tree and red red thyme-in comparison with AMB and ITZ against , and clinical isolates. Antifungal activity was determined by broth microdilution method, agar diffusion technique, fungistatic and fungicidal activities and vapor contact assay.
Results: Gas chromatography-mass spectrometry analysis displayed two groups of distinct biosynthetical origin: monoterpenes dominated the chemical composition of the most oils. Only two aromatic compounds (eugenol 78.91% and eugenyl acetate 11.64%) have been identified as major components in clove EO. Lemongrass EO exhibits the strongest antimicrobial activity with a minimum inhibitory concentration of 0.56 mg/mL and a minimum fungicidal concentration of 2.25-4.5 mg/mL against spp. strains. Clove and geranium EOs were fairly effective in inhibiting spp. growth.
Conclusions: These results demonstrate the antimicrobial potential of some EOs and support the research of new alternatives or complementary therapies based on EOs.
El-Sayed M, Alharbi M, Elsehemy I, Haggag W, Refaat B, Ali S J Microbiol Biotechnol. 2024; 34(10):2049-2069.
PMID: 39263788 PMC: 11540613. DOI: 10.4014/jmb.2404.04032.
Cavallo L, Menotti F, Roana J, Costa C, Longo F, Pagano C Pharmaceutics. 2024; 16(7).
PMID: 39065654 PMC: 11279409. DOI: 10.3390/pharmaceutics16070957.